129 results
20-F/A
2023 FY
IPCIF
Intellipharmaceutics International Inc.
6 Feb 24
Annual report (foreign) (amended)
12:00am
Purchasers.
Item 16F.
Change in Registrant’s Certifying Accountant.
Item 16G.
Corporate Governance.
Item 16H.
Mine Safety Disclosure.
PART III
Item 17 … .
The commencement of clinical trials can be delayed for a variety of reasons, including delays in:
demonstrating sufficient safety and efficacy to obtain
20-F/A
2023 FY
EX-4.87
IPCIF
Intellipharmaceutics International Inc.
6 Feb 24
Annual report (foreign) (amended)
12:00am
manufacturing controls documents, safety and efficacy study documents as applicable to the Product (“Product Data”) and (ii) other technical … , safety and efficacy data, formulary submissions, pharmaco-economic data, and other such information useful or required in preparing applications
6-K
EX-99.1
IPCIF
Intellipharmaceutics International Inc.
16 Oct 23
Current report (foreign)
5:23pm
other things, the availability of funding, design and formulation challenges, safety or efficacy, patent issues associated with the product, and FDA … safety and efficacy data for Oxycodone ER that may be obtained from human abuse potential studies for the oral and intranasal routes of administration
6-K
EX-99.1
IPCIF
Intellipharmaceutics International Inc.
26 Sep 23
Current report (foreign)
5:29pm
, safety or efficacy, patent issues associated with the product, and FDA and Health Canada review times.
Dexmethylphenidate Hydrochloride … . The Advisory Committees expressed a desire to review the additional safety and efficacy data for Oxycodone ER that may be obtained from human abuse
6-K
EX-99.1
IPCIF
Intellipharmaceutics International Inc.
26 Sep 23
Current report (foreign)
5:23pm
, the availability of funding, design and formulation challenges, safety or efficacy, patent issues associated with the product, and FDA and Health Canada … in the product label for the intravenous route of administration. The Advisory Committees expressed a desire to review the additional safety and efficacy
6-K
EX-99.1
silvx26lit41457
14 Oct 22
Current report (foreign)
4:22pm
6-K
EX-99.1
fhs8k1s75kan89t
21 Jul 22
Current report (foreign)
5:28pm
20-F/A
1sp10m
6 May 22
Annual report (foreign) (amended)
7:54pm
6-K
EX-99.1
vzept ljrawpdwoa
14 Apr 22
Current report (foreign)
4:46pm
6-K
EX-99.3
mzx5a2c2ku zfp
1 Mar 22
Current report (foreign)
8:04am
6-K
EX-99.1
3lta 9jellzt1halbgc
1 Mar 22
Current report (foreign)
8:04am
6-K
EX-99.1
oo1hxkfm9zd
28 Feb 22
Primary Document
9:56pm
6-K
EX-99.1
ksolop0t xsq8ld0
15 Oct 21
Current report (foreign)
5:22pm
6-K
EX-99.3
tox1rpdf yw
15 Oct 21
Current report (foreign)
5:22pm
6-K
EX-99.3
1ncuuucsk76j48 13bm
15 Jul 21
Primary Document
4:45pm
6-K
EX-99.1
8v4cwjrk9i0o0f
15 Jul 21
Primary Document
4:45pm
6-K
EX-99.1
15fc7orlr3
14 Apr 21
Primary Document
7:50am